HKI-357 / Pfizer - LARVOL DELTA

HKI-357 inhibits castration-resistant prostate cancer by targeting UBE2C via the AKT signaling pathway. (PubMed, Biochem Pharmacol) - "Furthermore, UBE2C, as a target of the androgen receptor (AR), shows upregulation in CRPC. In summary, our research demonstrated that HKI-357 can inhibit CRPC progression by targeting UBE2C via the AKT pathway, revealing a new drug mechanism of action and providing a promising therapeutic candidate for CRPC treatment."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Targeted Protein Degradation • UBE2C